← Leaderboards
Preston A Marx
Aaron Diamond Aids Research Center
$21,704,506
Attributed
$21,704,506
Total exposure
91
Grants
59
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.9M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$21,704,506 · 91
By mechanism
R01$7,131,269 · 3
P51$5,220,613 · 84
P01$4,874,815 · 1
R24$2,469,321 · 1
U19$1,812,824 · 1
P30$195,664 · 1
Top collaborators
No co-investigators on record.
Most similar at Aaron Diamond Aids Research Center
Same institution · by research overlap
- Cecilia C Cheng-Mayer$25,693,681
Others in their field
Top investigators on “Primates”
- Dennis R. Burton · Scripps Research Institute$282,976,433
- David Heimbrook · Leidos Biomedical Research, Inc.$244,980,072
- Richard A Gibbs · Baylor College Of Medicine$234,617,125
- Lawrence Corey · Fred Hutchinson Cancer Center$225,398,394
- Mark S Klempner · Tufts Medical Center$128,021,180
- Dan H. Barouch · Fred Hutchinson Cancer Center$119,529,020
Research focus
PrimatesUnited States National Institutes Of HealthFundingResourcesSourceResearch PersonnelAnimalsMacaca MulattaGrantInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseVirusMacacaAntibodiesBloodBlood SpecimenVaccinesMonkeysSamplingInfectionVaginaSimian Immunodeficiency VirusImmune ResponseMonitor
Grant awards (127)
Core Services: Division of Microbiology, Virus Characterization, Isolation and Production Core$49,487
P51 · FY2019 · OD · contact PI
Core Services: Division of Microbiology, Virus Characterization, Isolation and Production Core$49,487
P51 · FY2018 · OD · contact PI
Primate Studies$220,546
P01 · FY2013 · AI · contact PI
Pathogenesis of Natural SIV and STLV Infections in Humans$656,599
R01 · FY2012 · AI · contact PI
Efficacy and Toxicity of CSIC abd Retrocylin in the SIV Virus Challenge Model$413,286
U19 · FY2012 · AI · contact PI
Primate Studies$1,362,127
P01 · FY2011 · AI · contact PI
Pathogenesis of Natural SIV and STLV Infections in Humans$653,866
R01 · FY2011 · AI · contact PI
Efficacy and Toxicity of CSIC abd Retrocylin in the SIV Virus Challenge Model$550,389
U19 · FY2011 · AI · contact PI
PATHOGENESIS OF NATURAL SIV AND STLV INFECTIONS IN HUMANS$57,750
P51 · FY2011 · RR · contact PI
EFFICACY AND TOXICITY OF CSIC AND RETROCYCLIN IN THE SIV VAGINAL CHALLENGE MODEL$57,750
P51 · FY2011 · RR · contact PI
ISOLATION OF A NEW HIV-2 GROUP IN THE US$57,750
P51 · FY2011 · RR · contact PI
DNA VACCINE FOR INDUCTION OF MUCOSAL IMMUNITY$57,750
P51 · FY2011 · RR · contact PI
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES$57,750
P51 · FY2011 · RR · contact PI
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE$57,750
P51 · FY2011 · RR · contact PI
NHP PILOT STUDY OF A NOVEL PROTEIN ADJUVANT FOR VACCINES AGAINST HUMAN PATHOGENS$32,019
P51 · FY2011 · RR · contact PI
Primate Studies$991,499
P01 · FY2010 · AI · contact PI
Pathogenesis of Natural SIV and STLV Infections in Humans$648,307
R01 · FY2010 · AI · contact PI
Efficacy and Toxicity of CSIC abd Retrocylin in the SIV Virus Challenge Model$613,249
U19 · FY2010 · AI · contact PI
PATHOGENESIS OF NATURAL SIV AND STLV INFECTIONS IN HUMANS$61,801
P51 · FY2010 · RR · contact PI
EFFICACY AND TOXICITY OF CSIC AND RETROCYCLIN IN THE SIV VAGINAL CHALLENGE MODEL$61,801
P51 · FY2010 · RR · contact PI
PALOMA PHARMA 529 TREATMENT FOR SIV STUDY$61,801
P51 · FY2010 · RR · contact PI
ELICITATION OF BROAD IMMUNITY USING VLPS WITH CONSENSUS ENVS$61,801
P51 · FY2010 · RR · contact PI
DNA VACCINE FOR INDUCTION OF MUCOSAL IMMUNITY$61,801
P51 · FY2010 · RR · contact PI
ANTIBODY EFFECTOR FUNCTION PROTECTION AGAINST HIV-1$61,801
P51 · FY2010 · RR · contact PI
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES$61,801
P51 · FY2010 · RR · contact PI
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE$61,801
P51 · FY2010 · RR · contact PI
NHP PILOT STUDY OF A NOVEL PROTEIN ADJUVANT FOR VACCINES AGAINST HUMAN PATHOGENS$39,400
P51 · FY2010 · RR · contact PI
HIV ENV EPITOPE ENGINEERING$39,400
P51 · FY2010 · RR · contact PI
Primate Studies$882,699
P01 · FY2009 · AI · contact PI
Pathogenesis of Natural SIV and STLV Infections in Humans$647,843
R01 · FY2009 · AI · contact PI
Efficacy and Toxicity of CSIC abd Retrocylin in the SIV Virus Challenge Model$235,900
U19 · FY2009 · AI · contact PI
SIMIAN RETROVIRUS VACCINE FOR NON-HUMAN PRIMATES$60,376
P51 · FY2009 · RR · contact PI
ANTIBODY EFFECTOR FUNCTION PROTECTION AGAINST HIV-1$60,376
P51 · FY2009 · RR · contact PI
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES$60,376
P51 · FY2009 · RR · contact PI
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE$60,376
P51 · FY2009 · RR · contact PI
ELICITATION OF BROAD IMMUNITY USING VLPS WITH CONSENSUS ENVS$60,376
P51 · FY2009 · RR · contact PI
DNA VACCINE FOR INDUCTION OF MUCOSAL IMMUNITY$60,376
P51 · FY2009 · RR · contact PI
WEST NILE VACCINE FOR NON-HUMAN PRIMATES$57,967
P51 · FY2009 · RR · contact PI
Primate Studies$623,629
P01 · FY2008 · AI · contact PI
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE$64,630
P51 · FY2008 · RR · contact PI
ELICITATION OF BROAD IMMUNITY USING VLPS WITH CONSENSUS ENVS$64,630
P51 · FY2008 · RR · contact PI
DNA VACCINE FOR INDUCTION OF MUCOSAL IMMUNITY$64,630
P51 · FY2008 · RR · contact PI
SIMIAN RETROVIRUS VACCINE FOR NON-HUMAN PRIMATES$64,630
P51 · FY2008 · RR · contact PI
IMMUNE STIMULATION AND REDUCTION IN VIRAL LOAD USING THE ENERGEX HEMO-MODULATOR$64,630
P51 · FY2008 · RR · contact PI
ANTIBODY EFFECTOR FUNCTION PROTECTION AGAINST HIV-1$64,630
P51 · FY2008 · RR · contact PI
HIV VACCINE DESIGN AND DEVELOPMENT TEAM ? WYETH$64,630
P51 · FY2008 · RR · contact PI
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES$64,630
P51 · FY2008 · RR · contact PI
TOPICAL ESTROGEN PROTECTS AGAINST SIV VAGINAL TRANSMISSION$64,630
P51 · FY2008 · RR · contact PI
WEST NILE VACCINE FOR NON-HUMAN PRIMATES$24,103
P51 · FY2008 · RR · contact PI
Primate Studies$794,315
P01 · FY2007 · AI · contact PI
TREATMENT OF SIVMAC251 INFECTION IN MACAQUES WITH TARVACIN$71,639
P51 · FY2007 · RR · contact PI
TESTING EFFICACY OF ELUSYS HETEROPOLYMER AGAINST SHIV INFECTION IN MONKEYS$71,639
P51 · FY2007 · RR · contact PI
IMMUNE STIMULATION AND REDUCTION IN VIRAL LOAD USING THE ENERGEX HEMO-MODULATOR$71,639
P51 · FY2007 · RR · contact PI
ANTIBODY EFFECTOR FUNCTION PROTECTION AGAINST HIV-1$71,638
P51 · FY2007 · RR · contact PI
SIMIAN RETROVIRUS VACCINE FOR NON-HUMAN PRIMATES$71,638
P51 · FY2007 · RR · contact PI
HIV VACCINE DESIGN AND DEVELOPMENT TEAM ? WYETH$71,638
P51 · FY2007 · RR · contact PI
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES$71,638
P51 · FY2007 · RR · contact PI
TOPICAL ESTROGEN PROTECTS AGAINST SIV VAGINAL TRANSMISSION$71,638
P51 · FY2007 · RR · contact PI
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE$71,638
P51 · FY2007 · RR · contact PI
PROGESTERONE AND ESTROGEN ON SIV VAGINAL TRANSMISSION$66,250
R01 · FY2007 · AI · contact PI
WEST NILE VACCINE FOR NON-HUMAN PRIMATES$30,391
P51 · FY2007 · RR · contact PI
AN IMPROVED MACAQUE MODEL FOR SIV AND SHIV$238,047
R24 · FY2006 · RR · contact PI
PROGESTERONE AND ESTROGEN ON SIV VAGINAL TRANSMISSION$66,250
R01 · FY2006 · AI · contact PI
TOPICAL ESTROGEN TO THICKEN THE VAGINAL EPITHELIUM AND PREVENT INFECTIONS$65,435
P51 · FY2006 · RR · contact PI
NONINVASIVE DETECTION OF NEW SIV LINEAGES IN CAPTIVE SOOTY MANGABEYS$65,435
P51 · FY2006 · RR · contact PI
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE$65,435
P51 · FY2006 · RR · contact PI
TOPICAL ESTROGEN PROTECTS AGAINST SIV VAGINAL TRANSMISSION$65,435
P51 · FY2006 · RR · contact PI
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES$65,435
P51 · FY2006 · RR · contact PI
HIV VACCINE DESIGN AND DEVELOPMENT TEAM ? WYETH$65,435
P51 · FY2006 · RR · contact PI
ANTIBODY EFFECTOR FUNCTION PROTECTION AGAINST HIV-1$65,435
P51 · FY2006 · RR · contact PI
IMMUNOTHERAPY OF SIV INFECTED MONKEYS BY EXTRACORPOREAL UV IRRADIATION OF BLOOD$65,435
P51 · FY2006 · RR · contact PI
VACCINATION OF CHINESE-ORIGIN RHESUS WITH VSV-SIV HYBRID VIRUS$65,435
P51 · FY2006 · RR · contact PI
AN IMPROVED MACAQUE MODEL FOR SIV AND SHIV$461,666
R24 · FY2005 · RR
HIV VACCINE DESIGN AND DEVELOPMENT TEAM ? WYETH$54,500
P51 · FY2005 · RR
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES$54,500
P51 · FY2005 · RR
TOPICAL ESTROGEN PROTECTS AGAINST SIV VAGINAL TRANSMISSION$54,500
P51 · FY2005 · RR
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE$54,500
P51 · FY2005 · RR
NONINVASIVE DETECTION OF NEW SIV LINEAGES IN CAPTIVE SOOTY MANGABEYS$54,500
P51 · FY2005 · RR
ANTIBODY EFFECTOR FUNCTION PROTECTION AGAINST HIV-1$54,500
P51 · FY2005 · RR
LONGITUDINAL FOLLOW UP OF SIVMAC PATHOGENESIS IN MACAQUES OF CHINESE ORIGIN$54,500
P51 · FY2005 · RR
AN IMPROVED MACAQUE MODEL FOR SIV AND SHIV$483,829
R24 · FY2004 · RR
PROGESTERONE AND ESTROGEN ON SIV VAGINAL TRANSMISSION$412,538
R01 · FY2004 · AI
SIV VAGINAL TRANSMISSION IN THE ABSENCE OF A CERVIX$47,161
P51 · FY2004 · RR
HYBRID ORIGIN OF SIV IN CHIMPANZEES$47,161
P51 · FY2004 · RR
EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES$47,161
P51 · FY2004 · RR
STRUCTURE AND FUNCTION OF CC-CHEMOKINE RECEPTOR 5$47,161
P51 · FY2004 · RR
TOPICAL ESTROGEN TO PREVENT SIV VAGINAL TRANSMISSION$47,161
P51 · FY2004 · RR
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE$47,161
P51 · FY2004 · RR
NONINVASIVE DETECTION OF NEW SIV LINEAGES$47,161
P51 · FY2004 · RR
LONGITUDINAL FOLLOW UP OF SIVMAC PATHOGENESIS IN MACAQUES OF CHINESE ORIGIN$47,161
P51 · FY2004 · RR
THE EFFECT OF SINGLE EXON TAT IN PATHOGENESIS$47,161
P51 · FY2004 · RR
STUDIES OF SIVRCM AND RELATED PRIMATE LENTIVIRUSES$47,161
P51 · FY2004 · RR
EVIDENCE FOR DEEP PHYLOGENETIC DIVERGENCE IN MANDRILLUS$47,161
P51 · FY2004 · RR
SIV-RCM AND RELATED PRIMATE LENTIVIRUSES IN WEST AFRICA$629,175
R01 · FY2003 · AI
AN IMPROVED MACAQUE MODEL FOR SIV AND SHIV$602,611
R24 · FY2003 · RR
PROGESTERONE AND ESTROGEN ON SIV VAGINAL TRANSMISSION$595,331
R01 · FY2003 · AI
DOXYCYCLINE INDUCED IMMUNE RESPONSE TO NOVEL HIV VECTOR$77,693
P51 · FY2003 · RR
EFFECTS OF PROGESTERONE &ESTROGEN ON SIV VAGINAL TRANSMISSION$61,936
P51 · FY2003 · RR
INJECTABLE ANTIBIOTICS IN MEME DIVISION, IN THE SW PROVINCE OF CAMEROON$61,544
P51 · FY2003 · RR
ADDITION OF A SINGLE GP120 GLYCAN CONFERS INCREASED BINDING TO DENDRITIC CELL-SP$61,544
P51 · FY2003 · RR
BOOSTING OF SIV-SPECIFIC T-CELL RESPONSES IN RHESUS MACAQUES$61,544
P51 · FY2003 · RR
RHESUS MONKEY SIV INFECTION AS MODEL FOR ASSESSING THE ROLE OF SELENIUM IN AIDS$61,544
P51 · FY2003 · RR
NONINVASIVE DETECTION OF NEW SIV LINEAGES IN CAPTIVE SOOTY MANGABEYS$61,544
P51 · FY2003 · RR
STUDIES OF SIVRCM AND RELATED PRIMATE LENTIVIRUSES IN WEST AFRICA$61,544
P51 · FY2003 · RR
THE EFFECT OF SINGLE EXON TAT IN PATHOGENESIS$61,544
P51 · FY2003 · RR
LONGITUDINAL FOLLOW UP OF SIVMAC PATHOGENESIS IN MACAQUES OF CHINESE ORIGIN$61,544
P51 · FY2003 · RR
LACK OF EVIDENCE FOR SIVCPZ INFECTION IN CAPTIVE AND WILD CHIMPS$61,544
P51 · FY2003 · RR
INCREASED MACROPHAGE INFECTION UPON SUBCUTANEOUS INOCULATION OF RHESUS MACAQUES$61,544
P51 · FY2003 · RR
ENDOGENOUSLY EXPRESSED NEF UNCOUPLES CYTOKINE AND CHEMOKINE PRODUCTION$61,544
P51 · FY2003 · RR
AN IMPROVED MACAQUE MODEL FOR SIV AND SHIV$683,168
R24 · FY2002 · RR
SIV-RCM AND RELATED PRIMATE LENTIVIRUSES IN WEST AFRICA$584,440
R01 · FY2002 · AI
PROGESTERONE AND ESTROGEN ON SIV VAGINAL TRANSMISSION$271,658
R01 · FY2002 · AI
PROGESTERONE AND ESTROGEN ON SIV VAGINAL TRANSMISSION$224,531
R01 · FY2002 · AI
CORE--PRIMATE$0
P30 · FY2002 · AI
EFFECTS OF PROGESTERONE &ESTROGEN ON SIV VAGINAL TRANSMISSION: MENOPAUSE$0
P51 · FY2002 · RR
EARLY EVENTS OF MUCOSAL TRANSMISSION OF SIV &SHIV: SEXUAL TRANSMISSION$0
P51 · FY2002 · RR
SIV-RCM AND RELATED PRIMATE LENTIVIRUSES IN WEST AFRICA$525,903
R01 · FY2001 · AI
PROGESTERONE AND ESTROGEN ON SIV VAGINAL TRANSMISSION$472,048
R01 · FY2001 · AI
SIV-RCM AND RELATED PRIMATE LENTIVIRUSES IN WEST AFRICA$81,151
R01 · FY2001 · AI
CORE--PRIMATE$0
P30 · FY2001 · AI
EFFECTS OF PROGESTERONE &ESTROGEN ON SIV VAGINAL TRANSMISSION: MENOPAUSE$0
P51 · FY2001 · RR
EARLY EVENTS OF MUCOSAL TRANSMISSION OF SIV &SHIV: SEXUAL TRANSMISSION$0
P51 · FY2001 · RR
SIV-RCM AND RELATED PRIMATE LENTIVIRUSES IN WEST AFRICA$595,379
R01 · FY2000 · AI
CORE--PRIMATE$195,664
P30 · FY2000 · AI
EFFECTS OF PROGESTERONE &ESTROGEN ON SIV VAGINAL TRANSMISSION$54,327
P51 · FY2000 · RR
SIVRCM &RELATED PRIMATE LENTIVURSES IN WEST AFRICA$54,327
P51 · FY2000 · RR
EARLY EVENTS OF MUCOSAL TRANSMISSION OF SIV &SHIV$54,327
P51 · FY2000 · RR